Clinical Context
A typical patient is an adult diagnosed with thyroid eye disease (TED) experiencing progressive proptosis, diplopia, orbital pain, or corneal exposure despite standard therapy. The patient presents to an outpatient infusion center affiliated with an ophthalmology or endocrinology practice. A multidisciplinary visit (ophthalmologist and endocrinologist) documents indication, baseline ophthalmic exam including proptosis measurement, visual acuity, and diplopia assessment, and baseline laboratory tests and vital signs.
On the infusion day the patient is registered, allergy and consent are confirmed, and pre-infusion vitals are obtained. Teprotumumab-trbw is supplied in vials and prepared by pharmacy as an intravenous infusion; J3241 describes the billed drug unit (10 mg). The patient receives pre-medications per local protocol if required, is connected to the infusion pump, and monitored for infusion reactions. Post-infusion observation includes reassessment of vitals and ocular symptoms. Documentation includes drug name teprotumumab-trbw, dose in mg, number of J3241 units administered, infusion start and stop times, lot numbers, and any adverse events. Typical sites of service are hospital outpatient departments, physician office infusion suites, or independent infusion centers. Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.